Study Reveals Importance Of Timing For Cellular Signals, Suggests Possible Tactic For Cancer Therapeutics
Magic tricks work because they take advantage of the brain’s sensory assumptions, tricking audiences into seeing phantoms or overlooking sleights of hand. Now a team of UC San Francisco researchers has discovered that even brainless single-celled yeast have sensory biases that can be hacked by a carefully engineered illusion, a finding that could be used to develop new approaches to fighting diseases such as cancer.
“The ability to perceive and respond to the environment is a basic attribute of all living organisms, from the greatest to the smallest,” said Wendell Lim, PhD, the study’s senior author. “And so is the susceptibility to misperception. It doesn’t matter if the illusion is based on molecular sensors within a single cell or neurons in the brain.”
In the new study, published online Nov. 19, 2015 in Science Express, Lim and his team discovered that yeast cells falsely perceive a specifically timed pattern of stress – caused by alternating between low and mildly increased sodium levels – as a massive, continuously increasing ramp of stress. In response, the microbes end up over-responding and killing themselves. The results, Lim says, suggest a whole new way of looking at the perceptual abilities of simple cells and could even be used to develop new approaches to fighting diseases using the power of illusion.
Timing of stress response is yeast cells’ ‘Achilles heel’
“This discovery was a bit of an accident actually,” said Lim, chair of the Department of Cellular and Molecular Pharmacology at UCSF, director of the UCSF Center for Systems and Synthetic Biology, and a Howard Hughes Medical Institute (HHMI) investigator. “We were interested in the general issue of how cells interpret information over time. Frequency is a key aspect of all our communications, whether it’s hearing language or transmitting radio signals, but do cells themselves use this kind of information? It’s something we don’t know much about.”
To explore this question, two postdoctoral fellows in Lim’s lab, Ping Wei, PhD, now at Peking University School of Life Sciences, and Amir Mitchell, PhD, set up a system that allowed them to expose yeast to a mild stressor – a small increase in salt in the yeast’s environment – and to oscillate between the increased salt level and the baseline level at different frequencies.
Normally, sensor molecules in a yeast cell detect changes in salt concentration and instruct the cell to respond by producing a protective chemical. After this transient response, the cell can resume growing happily as if conditions had not changed. The researchers found that the cells were perfectly capable of adapting when they flipped the salt stress on and off every minute or every 32 minutes. But to their surprise, when they tried an eight-minute oscillation of precisely the same salt level the cells quickly stopped growing and began to die off.
“That was just a jaw-dropping moment,” said Mitchell. “These cells should be able to handle this level of osmotic stress, but at one particular frequency they just go haywire. We’d never seen anything like this before.”
Could sensory illusions be used to fight cancer?
Mitchell, who was first author on the new study, went on to inspect the cellular mechanism underlying this unexpected, frequency-dependent toxicity. Using mathematical modeling and experiments in which he tweaked the molecular wiring of the mitogen activated protein kinase (MAPK) pathway that mediates the cells’ salt-sensing system, he revealed a sensory misperception: Because of the way the MAPK pathway is set up, the cells interpret an eight-minute oscillation as an ever-increasing staircase of salt concentration. This leads to excessive activation of the cells’ protective response, and ultimately to their death (see Movie).
The Latest on: Cancer Therapeutics
via Google News
The Latest on: Cancer Therapeutics
- The Asia Pacific RNAi therapeutics market is expected to reach US$ 218.64 million by 2027 from US$ 107.63 million in 2019on November 27, 2020 at 9:56 am
Reportlinker.com announces the release of the report "Asia Pacific RNAi Therapeutics Market Forecast to 2027 - COVID-19 ...
- G1 Therapeutics: Depressed Price Before Catalyst, No Apparent Reasonon November 27, 2020 at 7:28 am
We were discussing G1 Therapeutics in our TPT member chat yesterday. It has been a depressed stock for over a year now, and even today, despite having a PDUFA date in less than 3 ...
- Bladder Cancer Therapeutics and Diagnostics Market Growing at 6.6% CAGR to Cross 551.5 million by 2025on November 26, 2020 at 1:28 pm
Selbyville, Delaware, The Global Bladder Cancer Therapeutics and Diagnostics Market Research Report 2020-2025 is ...
- Cancer Diagnostics Market to Reach US$311 Bn by 2027; Increased Efforts to Find New Therapeutics to Fuel Market Growth: TMRon November 25, 2020 at 6:30 am
In a recently published report, Transparency Market Research speaks about the global cancer diagnostics market and its future developments ...
- Breast Cancer Therapeutics Market Size to record 10.16% CAGR over 2020-2027on November 25, 2020 at 5:32 am
Global Breast Cancer Therapeutics Market is valued approximately at USD 19.57 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 10.16% over the forecast period ...
- Rapid Rise in Cases of Prostate Cancer Worldwide to Influence Growth of Prostate Cancer Therapeutics Market to a Great Extent: TMRon November 24, 2020 at 5:30 am
The prevalence of prostate cancer is magnifying across the world at a rapid rate. According to the estimates by the American Cancer ...
- Cancer Therapeutics Market Size, Share, Growth, Trends and Forecast 2030 – Amgen, Bayer, Johnson & Johnsonon November 23, 2020 at 1:10 am
Cancer Therapeutics Market is estimated to account for over US$ 140 billion by 2019. The market is anticipated to grow at a CAGR of ~7.7% from 2019 to 2030. The market growth can be attributed to ...
- G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS)on November 18, 2020 at 5:45 pm
for the treatment of ER+ breast cancer. In 2020, the company out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib. G1 Therapeutics ...
- AUM Biosciences and Newsoara Biopharma Announce a 5-year Transformational Strategic Partnership to Co-develop and Co-discover Next-generation Cancer Therapeuticson November 18, 2020 at 3:23 pm
AUM is building a diverse portfolio of small molecule therapeutics that target critical biological pathways. A core component of AUM’s strategy is mandating biomarkers and leveraging AI to ...
- PTC Therapeutics' cancer drug nabs Fast Track and Orphan Drug tags for rare indicationson November 18, 2020 at 10:37 am
The FDA has designated both Orphan Drug Designation and Fast Track status to ' (NASDAQ:PTCT) PTC596 for the treatment of leiomyosarcoma (LMS), a rare type of cancer that affects smooth muscle tissue.
via Bing News